ATH-1017-Treatment in patients with Parkinson’s Disease Dementia or DLB (Dementia with Lewy Bodies)
Disease/Condition: Parkinson’s Disease Dementia or Dementia with Lewy Bodies (DLB)
Enrollment Opens: 03/21/2022
Enrollment Closes: TBD
This clinical trial is evaluating the safety and efficacy of ATH-1017 treatment in patients with PDD (Parkinson’s Disease Dementia) or LBD (Lewy Bodies Dementia). The investigational compound (ATH-1017) is an agonist of the HGF/MET system and works to potentially reduce neuroinflammation, enhance synaptic plasticity and promote neural functioning in the brains of those experiencing either PDD or DLB.
Study ID: ATHIRA DLB/PDD 0201 (SHAPE)
To Enroll: Please call (503) 228-2273 (CARE) to schedule free memory lost testing and evaluation. Or contact http://www.summitresearchnetwork.com for additional informaton.
Posted by: Summit Headlands LLC | http://www.summitresearchnetwork.com